| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA955: Dupilumab for treating moderate to severe prurigo nodularis |
|
Medicine details |
|
| Medicine name | dupilumab (Dupixent®) |
| Formulation | subcutaneous injection |
| Reference number | 4734 |
| Indication | Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy |
| Company | Sanofi |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/04/2023 |
| NICE guidance | TA955: Dupilumab for treating moderate to severe prurigo nodularis |